GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...
GSK PLC on Tuesday said it had struck a deal to acquire asthma drug developer Aiolos Bio for up to $1.4 billion, as the British pharmaceutical giant pushes forward with plans to bolster its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results